Editas (EDIT) delivered earnings and revenue surprises of +28.57% and +498.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of -10.98% and -28.36%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.